Screener
EBITDA at other companies
Other financials
Where this comes from
Calculated from Travere Therapeutics, Inc.’s reported figures.
The source filing: Travere Therapeutics, Inc.’s 10-Q, filed May 4, 2026. Open the filing →
- Filed
- May 4, 2026, 4:45 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001438533-26-000042
FAQ
- What is Travere Therapeutics, Inc.'s EBITDA?
- Travere Therapeutics, Inc. (TVTX) reported EBITDA of -$11.7M in Q1 2026.
- How has Travere Therapeutics, Inc.'s EBITDA changed year-over-year?
- Travere Therapeutics, Inc.'s EBITDA increased by 60.8% year-over-year, from -$29.87M to -$11.7M.
- What is the long-term trend for Travere Therapeutics, Inc.'s EBITDA?
- Over 3 years (2022 to 2025), Travere Therapeutics, Inc.'s EBITDA has grown at a -80.9% compound annual growth rate (CAGR), from -$298.3M to -$2.08M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Travere Therapeutics, Inc.'s ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude